Project Grant F32DK146743
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded The University of Central Florida Board of Trustees $1.494 million under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a three-year project spanning September 1, 2025, through August 31, 2028. The project investigates the role of tau phosphorylation in diabetic peripheral neuropathy (DPN), a condition affecting millions globally. The research will identify mechanisms linking...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded a $4.04 million Project Grant to the University of Texas at Dallas for a three-year initiative (September 1, 2025 through August 31, 2028) to identify and validate therapeutic targets for chronic pain treatment. The project leverages a CRISPR-based functional genomic screening platform developed by collaborating researchers at the University of Sydney and an extensive human dorsal root ganglion...
- This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $170,100 to the University of New Mexico Health Sciences Center on September 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of proline-rich protein 14 (PRR14) in oxaliplatin-induced peripheral neuropathy (OIPN). This two-year project, scheduled for completion on August 31, 2027, addresses a critical gap in understanding chemotherapy-induced...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $441,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Duquesne University of the Holy Spirit. The purpose of this 3-year grant, beginning September 2023, is to utilize laboratory data and computational 3-D modeling to analyze the role of the central amygdala in neuropathic pain. Specifically, the project aims to build a proof-of-concept 3-D...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...
METHYLGLYOXAL-MEDIATED ACTIVATION OF THE INTEGRATED STRESS RESPONSE PROMOTES EIF2A-DEPENDENT TRANSLATION IN DIABETIC NEUROPATHIC PAIN - PROJECT SUMMARY/ABSTRACT DIABETIC NEUROPATHIC PAIN (DNP) IS A DEBILITATING COMPLICATION OF DIABETES THAT AFFECTS MILLIONS OF INDIVIDUALS WORLDWIDE, YET ITS UNDERLYING MOLECULAR MECHANISMS REMAIN POORLY UNDERSTOOD, AND EFFECTIVE TREATMENTS ARE LIMITED. EMERGING EVIDENCE IMPLICATES METHYLGLYOXAL (MGO), A REACTIVE GLYCOLYSIS BYPRODUCT, IN THE DEVELOPMENT OF DNP, POTENTIALLY THROUGH ACTIVATION OF THE INTEGRATED STRESS RESPONSE (ISR). THE ISR REGULATES MRNA TRANSLATION UNDER CELLULAR STRESS AND HAS BEEN LINKED TO NOCICEPTOR HYPEREXCITABILITY. OUR RESEARCH SEEKS TO INVESTIGATE HOW MGO-INDUCED ISR ACTIVATION ALTERS TRANSLATIONAL CONTROL IN NOCICEPTORS, WITH A SPECIFIC FOCUS ON THE ROLE OF EIF2A IN DRIVING ISR-MEDIATED PROTEIN SYNTHESIS THAT CONTRIBUTES TO PAIN HYPERSENSITIVITY IN DNP. SPECIFIC AIM 1 WILL USE A TRANSLATIONAL APPROACH THAT INTEGRATES NEXT-GENERATION SEQUENCING (TRAP-SEQ, RIBO- SEQ) IN MOUSE AND HUMANS. SPECIFIC AIM 2 WILL UTILIZE GENE EDITING (CRISPR-CAS9), AND FUNCTIONAL ASSAYS (CALCIUM IMAGING, PAIN BEHAVIOR) IN MOUSE, RAT, AND HUMAN NOCICEPTORS. TOGETHER, THE AIMS WILL DEFINE CONSERVED AND SPECIES-SPECIFIC MECHANISMS LINKING DIABETES, ISR ACTIVATION, AND NOCICEPTOR DYSFUNCTION. THIS FELLOWSHIP WILL PROVIDE RIGOROUS TRAINING IN MOLECULAR NEUROSCIENCE, RNA SEQUENCING, BIOINFORMATICS, AND TRANSLATIONAL DIABETES AND PAIN RESEARCH TO ENSURE A STRONG FOUNDATION IN BOTH EXPERIMENTAL AND COMPUTATIONAL TECHNIQUES. THE TRAINING ENVIRONMENT CONSISTS OF COLLABORATIVE RESEARCH SETTING WITH ACCESS TO STATE-OF-THE-ART SEQUENCING TECHNOLOGIES, PRIMARY HUMAN DRG CULTURES, AND ESTABLISHED PRECLINICAL MODELS OF DIABETES, OFFERING AN UNPARALLELED OPPORTUNITY TO BRIDGE MECHANISTIC STUDIES WITH CLINICAL RELEVANCE. BY INVESTIGATING NOVEL ISR-DRIVEN MECHANISMS UNDERLYING NOCICEPTOR DYSFUNCTION IN DNP, THIS PROJECT AIMS TO IDENTIFY NEW MOLECULAR TARGETS FOR OBJECTIVE DNP DIAGNOSIS, DEVELOPING NEW MODELS TO STUDY DNP, FOR POSSIBLE NEW AVENUES FOR THERAPEUTIC INTERVENTION, AND IMPROVING THE QUALITY OF LIFE FOR INDIVIDUALS WITH DIABETES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $76.3k | 5/7/26 |